Ameritas Investment Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Ameritas Investment Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,784	Closed	-$299K	–	3287
2023 Q1	$299K	Hold	2,784	–	–	0.01%	906
2022 Q4	$322K	Buy	2,784 +468	+20%	+$30.3K	0.01%	900
2022 Q3	$136K	Hold	2,316	–	–	0.01%	1291
2022 Q2	$65K	Hold	2,316	–	–	﹤0.01%	1826
2022 Q1	$87K	Hold	2,316	–	–	﹤0.01%	1741
2021 Q4	$92K	Buy	2,316 +1,430	+161%	+$44.8K	﹤0.01%	1738
2021 Q3	$21K	Hold	886	–	–	﹤0.01%	2685
2021 Q2	$22K	Buy	+886	New	+$19.8K	﹤0.01%	2700

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Ameritas Investment Partners's RXDX Position: Q2 2023 in Review

Ameritas Investment Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,784 shares — an estimated $299K sold.

Ameritas Investment Partners first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $322K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Ameritas Investment Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ameritas Investment Partners sold 2,784 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $299K.
Ameritas Investment Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Ameritas Investment Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $322K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.